24th Annual University of Chicago Developmental Therapeutics Symposium
At the conclusion of this activity, participants will be able to:
- State the effects of novel experimental agent usage from the National Cancer Institute and other sponsors;
- Cite the relevant pharmacology and biologic effects of novel anti-cancer agents through the use of blood and tissue samples as well as standard and novel imaging approaches;
- Identify how to assess patient suitability for participation in upcoming cancer clinical trials and projects;
- Discuss advances in the use of chemotherapy and other targeted therapies for cancer;
- Describe the rationale for and results of studies that include new targeted agents for the treatment of patients with advanced and rare diseases;
- Summarize how updated regulatory and data operations information can support clinical trial conduct as administrative systems evolve.
Agenda subject to change.
Want to know more?
ACCESSIBILITY The University of Chicago is committed to providing equal access appropriate to need and circumstances and complies fully with legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact our office at 773-702-9856 or via email at email@example.com.
The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, The University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.
Fred C. Buffett Professor of Medicine and Surgery
Chief, Section of Hematology/Oncology
Director, Genitourinary Oncology Program
Deputy Director, Comprehensive Cancer Center
Associate Professor of Medicine
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months, including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 4.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Claiming Credit: Enter the access code to unlock the credit claiming process.
Please Note: Requests to claim MOC Part II credit must be made within one month to report to the ABIM. Requests to claim AMA PRA Category 1 Credit™ after three months will be subject to additional fees.